Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Interleukin-4 (IL-4)
100%
Interleukin-13 (IL-13)
100%
Molecular Targets
100%
Severe Asthma
100%
Interleukin-5 (IL-5)
100%
Biologic Therapy
100%
Significant Clinical Benefit
40%
Airway
20%
Monoclonal Antibody
20%
Therapeutic Potential
20%
Clinical Features
20%
Asthmatic
20%
Eosinophils
20%
Chronic Inflammatory Diseases
20%
Signaling Cascades
20%
Asthma Phenotypes
20%
Blockage
20%
Complex Interplay
20%
Cytokine Receptor
20%
Head-to-head Trials
20%
Cytokine Pathways
20%
Eosinophil Count
20%
Severe Atopic Dermatitis
20%
Therapeutic Monoclonal Antibody
20%
Interleukin-4 Receptor
20%
Biomarker Characteristics
20%
Phenotype Selection
20%
Severe Eosinophilic Asthma
20%
Th2 Inflammatory Response
20%
Feature Characteristics
20%
Monoclonal Antibody Targeting
20%
Phase 3 Trial
20%
Biologic Mechanisms
20%
Medicine and Dentistry
Interleukin 4
100%
Interleukin 13
100%
Interleukin 5
100%
Severe Asthma
100%
Biological Therapy
100%
Cytokine
75%
Biological Product
75%
Monoclonal Antibody
50%
Asthma
50%
Eosinophil
50%
Biological Marker
25%
Inflammatory Disorder
25%
Serositis
25%
Clinical Feature
25%
Eosinophilic
25%
Atopic Dermatitis
25%
Monoclonal Antibody Therapy
25%
Interleukin 4 Receptor
25%
Cytokine Receptor
25%
Immunology and Microbiology
Interleukin 13
100%
Interleukin 4
100%
Severe Asthma
100%
Interleukin 5
100%
Cytokine
75%
Biological Product
75%
Monoclonal Antibody
50%
Asthma
50%
Inflammation Response
25%
Eosinophil
25%
Inflammatory Disorder
25%
Cytokine Receptor
25%
Eosinophil Count
25%
Airway
25%
Atopic Dermatitis
25%
Interleukin-4 Receptor
25%
Monoclonal Antibody Therapy
25%